TMCnet News

VIVO INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Meridian Bioscience, Inc. Investors and Encourages Investors to Contact the Firm
[January 10, 2018]

VIVO INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Meridian Bioscience, Inc. Investors and Encourages Investors to Contact the Firm


Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Meridian Bioscience, Inc. ("Meridian Bioscience" or the "Company") (NASDAQ: VIVO) securities between March 25, 2016 and July 13, 2017, inclusive (the "Class Period") Meridian Bioscience investors have until January 16, 2018 to file a lead plaintiff motion.

Investors suffering losses on their Meridian Bioscience investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].

On May 17, 2017, the U.S. Food and Drug Administration ("FDA") issued a warning to Meridian that lead tests conducted by the Company's subsidiary, Magellan (News - Alert) Diagnostics, may be incorrect. According to the FDA, tests performed on blood drawn from a vein has led to"results that are lower than the actual level of lead in the blood." The FDA has recommended discontinuation of Magellan when testing with venous blood samples. On this news, Meridian shares fell over 9% on May 17, 2017. Then on May 25, 2017, Meridian's Magellan Diagnostics announced a Class 1 recall of its LeadCare Plus and Ultra Testing Systems due to "inaccurate test results," according to the FDA.



On June 6, 2017 Meridian's Magellan Diagnostics subsidiary expanded the recall to incorporate the Company's LeadCare and LeadCare II testing systems. According to the FDA, the expansion of the recall was necessitated by "inaccurate test results when processing venous blood samples." On this news, shares of Meridian traded as low as $13.40 per share.

The complaint alleges that throughout the class period Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Defendant's lead tests provide inaccurate results; and (2) consequently, Meridian's public statements were materially false and misleading at all relevant times.


If you purchased shares of Meridian Bioscience, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


[ Back To TMCnet.com's Homepage ]